Search

everythinglearnresearchcommunity

for

Search:↓

Exploring the idea of transplanting miniaturized hair follicles to healthier areas to potentially reverse hair loss, with concerns about DHT sensitivity and scar tissue formation. The conversation also humorously considers using mice for hair growth experiments.

SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.

Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.

The conversation discusses starting low-dose oral finasteride for hair loss, considering hormone levels and potential side effects like gynecomastia. Suggestions include using DIM for estradiol, vitamin B6 for prolactin, and lifestyle changes to optimize hormone profiles before starting treatment.

The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.

Autologous exosome treatment for hair loss is being discussed as an emerging option. Minoxidil, finasteride, and RU58841 are also mentioned as treatments.

12 companies having drugs or therapies in clinical trials during 2023, with various molecules and phases of trial; the probability that some may fail; and progress being made in the field.

A user wants to make a solution for RU58841 and finasteride powder using only glycerin and asks if ethanol is necessary. They are seeking advice on whether glycerin alone is sufficient.

The conversation discusses the potential of Verteporfin, an FDA-approved drug, for hair loss treatment, particularly in combination with microneedling or PRP. Users express hope and curiosity about its application, while some remain cautious due to the need for more extensive testing.

The conversation is about a user planning a blood test to monitor health while on hair loss treatments: Finasteride, Minoxidil, and Dutasteride. Recommendations include testing for androgens, thyroid function, micronutrients, and basic health markers, with additional suggestions for PSA, prolactin, and estradiol.

Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.

The user is using 0.1% dutasteride, 1% minoxidil with 2% procapil and 0.005% caffeine in the morning, and 1% minoxidil with 2% procapil and 0.01% tretinoin at night. They are concerned about the solution vehicle's effectiveness in preventing systemic absorption and ensuring the products stay around the hair follicles.

The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.

The conversation is about the progress of verteporfin in hair loss trials, with users expressing curiosity about its effectiveness and updates. Specific treatments mentioned include FUE (Follicular Unit Extraction) combined with verteporfin, with one reported case of donor area regrowth after a year, and three patients being monitored post-treatment by Dr. Bloxham with monthly updates on YouTube.

GT20029 and PP405 are discussed as potential alternatives or complements to finasteride for hair loss treatment. GT20029 is entering phase 3 trials, while PP405 is seen as promising for regrowing hair and possibly eliminating the need for other treatments.

The conversation discusses the potential of using topical estrogen treatments for hair loss without systemic absorption, highlighting challenges and possible solutions like using estriol. It also mentions other treatments like topical finasteride, microneedling, and scalp massage, while noting the limitations and side effects of current options.

Hair cloning and injection of dermal papilla cells are discussed, with skepticism about their availability by 2023. Users mention Minoxidil, finasteride, and hair transplants as current treatments.

A case study that suggests verteporfin may be able to help regrow donor hairs after FUE extraction, and the potential implications of this result. Treatments discussed include Minoxidil, Finasteride, and RU58841.

Kintor is producing a cosmetic with KX826, starting at 0.5% concentration and moving to 1%. The 0.5% concentration wasn't as effective as minoxidil and finasteride, but the 1% concentration shows promise.

A user is considering starting finasteride for hair thinning but is concerned about side effects like low libido and gynecomastia. They plan to consult a dermatologist and are advised to test DHT, testosterone, and estradiol levels.

The conversation is about two new videos on exosomes, focusing on how they work and a Q&A session about their use. Specific treatments for hair loss are not discussed.

A 43-year-old male with advanced hair loss is experimenting with alternative treatments, including red light therapy, microneedling, scalp massages, an oil mix, and ketoconazole shampoo, after previously experiencing side effects from finasteride and minoxidil. He noticed some minor changes with red light therapy but remains skeptical about significant improvement.

The conversation discusses whether to get a blood test to check DHT levels while using Dutasteride for hair loss and concerns about Quercetin's potential interaction with Dutasteride. It concludes that testing DHT isn't necessary unless no effects are seen, and the small amount of Quercetin in a multivitamin likely doesn't interfere with treatment.

Han Bio plans to start Phase 1 clinical trials for a hair growth treatment in 2027 after successful results in mice. Many users express skepticism about the effectiveness of treatments that work on mice but not on humans, and discuss existing treatments like finasteride and minoxidil.

Finasteride is more accepted than hair systems because it is less visible and maintains natural hair. Treatments like minoxidil and finasteride are commonly used for hair loss, but opinions on hair systems vary.

The conversation discusses using a violet ray device for hair regrowth, citing a case where zinc ion treatments showed promising results. It also mentions similar devices like the Growcombr and niostem helmet.

An 18-year-old is considering testosterone replacement therapy with finasteride or dutasteride for hair loss but worries about side effects. Users recommend alternatives like minoxidil, RU58841, and consulting a doctor.

The user received a Fagron TrichoTest indicating that Finasteride, Dutasteride, and Minoxidil are not effective for them, recommending Latanoprost, Spironolactone, IGrantine-F1 TM, and Trichoxidil instead. Other users expressed skepticism about the test's validity and suggested sticking with proven treatments like Finasteride and Dutasteride.

A trial of verteporfin for hair regeneration, with pictures comparing the original and current status, as well as links to other resources discussing the efficacy of this treatment in combination with Minoxidil, Finasteride, and RU58841.

The conversation discusses skepticism about the effectiveness and formulation of a $10 RU58841 gel from a Korean brand, questioning if ethanol is used to hold the active compounds. Concerns are raised about the feasibility of selling it at such a low price.